David Tuller returns to discuss the continuing saga of the UK’s PACE trial for chronic fatigue syndrome, including the accusation that he is engaging in libelous blogging. You can find this TWiV Special at microbe.tv/twiv, or listen below. Click arrow to play Download TWiV Special (31 MB .mp3, 50 min) Subscribe (free): iTunes, RSS, email Become a patron of TWiV!
The microbes that live on and in us provide a host of functions that are essential for our health. Changes in the composition of these microbial communities correlate with a variety of disease states. Results of a new study (link) reveal altered populations of intestinal bacteria and metabolic disturbances in ME/CFS patients. The study subjects were …
Journalism professor David Tuller returns to TWiV for a discussion of the PACE trial for ME/CFS: the many flaws in the trial, why its conclusions are useless, and why the data must be released and re-examined. You can find TWiV #397 at microbe.tv/twiv, or listen below. [powerpress url=”http://traffic.libsyn.com/twiv/TWiV397.mp3″] Click arrow to play Download TWiV 397 (67 MB …
By David Tuller, DrPH David Tuller is academic coordinator of the concurrent masters degree program in public health and journalism at the University of California, Berkeley. In 2010, the BMJ published the results of the Fatigue Intervention by Nurses Evaluation, or FINE. The investigators for this companion trial to PACE, also funded by the Medical …
On episode #345 of the science show This Week in Virology, the TWiVonauts review how the weather affects West Nile virus disease in the US, benefit of B cell depletion for ME/CFS patients, and an autoimmune reaction induced by influenza virus vaccine that leads to narcolepsy. You can find TWiV #345 at www.microbe.tv/twiv.
Patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) showed clinical improvement after extended treatment with the anti-B-cell monoclonal antibody rituximab. This result suggests that in a subset of patients, ME/CFS might be an autoimmune disease. Rituximab is a monoclonal antibody against a protein on the surface of B cells known as CD20. When the antibody is given to …
